Clinical Trials Logo

Clinical Trial Summary

Bright Light Therapy (BLT) is a proven treatment for depression in seasonal and non-seasonal depressive disorders, as well as bipolar disorder. To make BLT more effective and practical in clinical settings and tailor it to individual needs, it is necessary to optimize the treatment approach, understand how the treatment works, and identify patient characteristics that predict response. This clinical trial has three main goals: - Optimize the administration of BLT for patients with depressive episodes. - Gain a deeper understanding of the treatment mechanisms. - Determine which patients benefit the most from the treatment. The specific objectives are as follows: - Investigate whether additional treatments and interventions related to lifestyle and the biological clock can enhance the effects of BLT. - Examine how BLT influences the body's internal clock and sleep quality, and how these factors contribute to the outcomes. - Identify patient characteristics and behaviours that can predict treatment outcomes. - Develop a brain model to better understand the impact of BLT on the brain. In this study, patients will receive BLT with a light intensity of 10,000 lux for 30 minutes each morning over 5 consecutive days. The treatment duration will range from one to three weeks, depending on the improvement of depressive symptoms. Participants will be randomly assigned to one of three groups: - Home - Patients will receive BLT at home, following the standard guidelines for light therapy in the Netherlands. - LightCafé, fixed time: Patients will receive BLT in a café-like setting called the LightCafé, where the focus is not only on symptom improvement but also lifestyle enhancements and fostering social connections. The treatment time will be the same every day. - LightCafé, varying time: Patients will also receive BLT at the LightCafé, with treatment timing varying each day. Additionally, this group will wear glasses in the evening that filter blue light. The study includes a baseline phase of up to two weeks, a treatment phase of up to three weeks, and a three-month follow-up phase. Patients will wear a motion watch to assess sleep-wake behaviour and physical activity during the day. Additionally, they will wear a broach that measures their personal light exposure throughout the day. Eight one-minute questionnaires per day will be sent to the participants' smartphones to assess vitality, sleep, and mood during the treatment. Predictors of treatment response, such as clinical characteristics, sleep measures, circadian parameters, and light-related behaviours, will be evaluated at baseline. In a small group of patients, salivary melatonin curves will be assessed before and after treatment. MRI scans will provide insights into functional and structural brain changes following light therapy treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05958940
Study type Interventional
Source Universiteit Leiden
Contact Niki Antypa, PhD
Phone +31 71 527 6677
Email nantypa@fsw.leidenuniv.nl
Status Not yet recruiting
Phase N/A
Start date September 2023
Completion date December 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05114824 - Acceptability and Feasibility of an 8-week Online Mindfulness-Based Cognitive Therapy Program Among Undergraduate Students N/A
Completed NCT03556735 - Pulsed Electro Magnetic Fields (PEMF) in Depression N/A
Completed NCT04916548 - Repeated Neurocognitive Measurements in Depressed Patients Phase 1/Phase 2
Recruiting NCT05767073 - LIVES: Personalized Lifestyle Intervention for Patients With Depression N/A
Recruiting NCT06094907 - Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression Phase 2
Completed NCT04121091 - Pramipexole to Target "Anhedonic Depression" Phase 2
Recruiting NCT06092411 - Effects of CBT and BLT in Youth With Unipolar Depression and Evening Chronotype N/A
Enrolling by invitation NCT03847688 - Machine Learning to Predict Clinical Response to TMS
Completed NCT02945735 - Gaze Contingent Feedback in Major Depressive Disorder (MDD) N/A
Recruiting NCT06139159 - CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos N/A
Recruiting NCT05011864 - Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression N/A
Terminated NCT03537547 - Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder Phase 4
Completed NCT03515733 - PF-04995274 and Emotional Processing in Treatment Resistant Depression Phase 1
Not yet recruiting NCT05991232 - Repeated Neurocognitive Measurements in Depressed Patients Phase 1/Phase 2
Completed NCT03516604 - PF-04995274 and Emotional Processing in Un-medicated Depression Phase 1
Completed NCT03538275 - Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
Active, not recruiting NCT03096886 - Novel Neural Circuit Biomarkers of Major Depression Response to CCBT N/A
Completed NCT01874951 - Low-Dose Naltrexone for Depression Relapse and Recurrence Phase 2
Completed NCT03906175 - Whole-body Hyperthermia for Mild to Moderate Depressive Disorder N/A
Active, not recruiting NCT05930912 - Psychiatric Orders in Psychoanalytic Treatment of ASD